CG
ABCL icon

Cutler Group’s AbCellera Biologics ABCL Stock Holding History

Cutler Group’s Portfolio ABCL Stock Details ABCL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-9,400
Closed -$95K – 3670
2022
Q4 		$95K Buy
9,400
+2,654
+39% +$30.7K 0.01% 1180
2022
Q3 		$66K Buy
+6,746
New +$74K ﹤0.01% 1692
2022
Q2 		– Sell
-2,200
Closed -$18.6K – 4867
2022
Q1 		$21K Sell
2,200
-3,191
-59% -$30.2K ﹤0.01% 2994
2021
Q4 		$77K Buy
5,391
+4,601
+582% +$69.8K ﹤0.01% 2047
2021
Q3 		$15K Sell
790
-2,810
-78% -$49.7K ﹤0.01% 3570
2021
Q2 		$79K Buy
3,600
+2,200
+157% +$60.7K ﹤0.01% 2070
2021
Q1 		$47K Buy
+1,400
New +$55.8K ﹤0.01% 2449

Other funds holding ABCL

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VOYA Investment Management
VOYA Investment Management Atlanta, Georgia $116B AUM 61.47% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
HMC
Harvard Management Company Boston, Massachusetts $4.26B AUM 5.81% 1-Year Est. Return
FFVM
Founders Fund VII Management San Francisco, California $2.03M AUM 72.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Cutler Group's ABCL Position: Q1 2023 in Review

Cutler Group sold out of AbCellera Biologics (ABCL) in Q1 2023, closing a stake of 9,400 shares — an estimated $95K sold.

Cutler Group first reported a position in ABCL in Q1 2021 and held it in 7 quarters. The position peaked at $95K in Q4 2022. 183 funds tracked by Wall St. Rank hold ABCL as of Q1 2023.

  • Cutler Group reported no remaining AbCellera Biologics position as of Q1 2023 after selling out during the quarter.
  • Cutler Group sold 9,400 AbCellera Biologics shares in Q1 2023, an estimated $95K.
  • Cutler Group first reported a position in AbCellera Biologics in Q1 2021 and held it in 7 quarters.
  • Cutler Group's AbCellera Biologics position peaked at $95K in Q4 2022.
  • 183 funds tracked by Wall St. Rank held AbCellera Biologics as of Q1 2023.

Based on Cutler Group's 13F filing for Q1 2023, filed 1 May 2023.